Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Celldex Therapeutics (CLDX) Tax Provisions (2017 - 2021)

Celldex Therapeutics has reported Tax Provisions over the past 4 years, most recently at $27000.0 for Q4 2021.

  • Quarterly results put Tax Provisions at $27000.0 for Q4 2021, down 97.0% from a year ago — trailing twelve months through Dec 2021 was $700000.0 (changed 0.0% YoY), and the annual figure for FY2021 was -$200000.0, up 82.86%.
  • Tax Provisions for Q4 2021 was $27000.0 at Celldex Therapeutics, up from -$227000.0 in the prior quarter.
  • Over the last five years, Tax Provisions for CLDX hit a ceiling of $900000.0 in Q4 2020 and a floor of -$19.1 million in Q4 2017.
  • Median Tax Provisions over the past 4 years was -$213500.0 (2020), compared with a mean of -$3.1 million.
  • Peak annual rise in Tax Provisions hit 97.0% in 2021, while the deepest fall reached 97.0% in 2021.
  • Celldex Therapeutics' Tax Provisions stood at -$19.1 million in 2017, then surged by 100.18% to $35000.0 in 2018, then surged by 2471.43% to $900000.0 in 2020, then plummeted by 97.0% to $27000.0 in 2021.
  • The last three reported values for Tax Provisions were $27000.0 (Q4 2021), -$227000.0 (Q3 2021), and $900000.0 (Q4 2020) per Business Quant data.